Put SPEX On You RADAR Immediately!
OTCtipReporter Newsletter
SPEX Is On HIGH ALERT! Unusual trading activity has recently grabbed my attention.
Turn our attention to SPEX In the past month SPEX has gone from $6.00 to $12… I believe SPEX is gearing up for a major breakout! Symbol: SPEX Co: Spherix Incorporated Alert Price: $12.85 Spherix Inc. (SPEX) is a shell that has sold off most of its core operations and now is in the process of purchasing over 222 patents and converting to a business model that to me is very similar to Acacia Research Corporation (ACTG), which has a billion dollar market cap.
SPEX and ACTG have several things in common. They both started as reverse splits with floats under one million. They then both devoted resources to purchasing and monetizing patents. They both have invested in a broad portfolio of patents, not just focusing on one patent or industry. ACTG did this years and years ago and has been very successful. SPEX is at the phase ACTG was at in its inception.
Spherix previously announced an agreement to acquire 222 patents from North South Holdings, Inc. principally developed by inventors at Harris Corp. (HRS), a 118 year old pioneer in wireless communications and equipment and a $6 billion defense contractor.
The Harris portfolio has applicability in law enforcement communications, military and homeland security, satellite communications, portable electronics, Wi-Fi, microwave and cellular transmission, and solar concentrator technologies. Additional North South patents cover automated pharmacy ordering practices.
Additionally, SPEX recently signed a further letter of intent with a major private patent ownership collaboration covering additional areas of telephony and telecommunications technology which they expect to close in the third quarter.
What I like about the patent portfolio they are acquiring is that it was developed at Harris Corp., and covers multiple growing industries. SPEX has stated in presentations that their goal is to monetize these patents by defense and licensing deals, much like the strategy of ACTG.
Several other companies have entered the patent field and have yet to monetize their patents but have grown to have large market caps.
1. Vringo Inc. (VRNG) has a market cap of $253 million.
2. Parkervision Inc. (PRKR) has a market cap of $424 million.
3. VirnetX Holding Co. has a market cap of $993 million.
Yahoo Finance currently reports SPEX to have a market cap of just $10m! Risks include the inability to monetize the patents or the need for more funding to mount legal defenses. However, with VRNG and PRKR they both significantly appreciated in market cap despite the fact they have yet to be successful in monetization.
Given the fact that SPEX`s portfolio was developed at a multi-billion dollar company such as HRS and that they cover multiple high-growth billion dollar industries, SPEX should be one to watch for significant appreciation from current levels as VRNG and PRKR made large moves as they converted to patent monetization companies.
Lastly, in my opinion, given its small public float of 650,000, SPEX could be a big mover once these comparisons are made. SPEX initially moved to $14.99 when the transformation to a patent company was initially announced back in March of 2013. Now that they have given a timeframe to close and defined the 222 patents more clearly, I believe SPEX could be ready to renew its move higher.
As always we encourage subscribers to do their own due diligence and visit the company website: www.spherix.com Be on High Alert and Ready to Act! Stay Tuned! Happy Trading!! The OTCtipReporter Team DONT MISS ANOTHER HOT OPPORTUNITY TO MAKE HUGE PROFITS! GENERAL NOTICE AND DISCLAIMER – PLEASE READ CAREFULLY The companies that are discussed on OTCtipReporter.com have not approved the statements made. This opinion contains forward-looking statements that involve risks and uncertainties. A company`s actual results could differ materially from those described in any forward-looking statements or announcements discussed herein. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. OTCtipReporter.com is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Nor are any of its officers, affiliates, or employees. Please consult a broker before purchasing or selling any securities viewed on OTCtipReporter.com or mentioned herein.
Affiliates, officers, directors and employees of OTCtipReporter.com may have also bought or may buy shares of companies mentioned herein and may profit in the event those shares rise in value.
OTCtipReporter.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make their own decision based on his or her judgment of the market. This advertisement is not a solicitation or recommendation to buy, sell or hold securities and does not provide an analysis of the financial position of the company. We recommend you use the information found in this advertisement as an initial starting point for conducting your own research on the advertised company in order to determine your own personal opinion of the company before investing. All statements and opinions contained in this advertisement are the sole opinion of the authors and are subject to change without notice. We are not liable for any investment decisions by our readers. Readers should independently investigate and fully understand all risks before investing. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser or broker prior to completing any such purchase or sale decision. We are not registered investment advisers, or broker-dealers, or members of any financial regulatory bodies. Furthermore, our associates and/or employees and/or principals may have stock positions in advertised companies purchased in the open market or in private transactions.
These positions may be liquidated, without prior notification, even after we have made positive comments regarding the advertised company. The receipt of this information constitutes your acceptance of these terms and conditions. Reading this advertisement shall not create under any circumstances an offer to buy or sell stock in any company advertised. Nor shall it create any principal-agent relationship between the reader and us. Void where prohibited. Information within this advertisement contains “forward looking” statements within the meaning of Section-27(a) of the U.S. Securities Act-of-1933 and Section 21(e) of the U.S.
Securities Exchange Act-of -934. Neither OTCtipReporter.com, its officers, affiliates, or employees is a broker-dealer. The information on OTCtipReporter.com, including the opinions expressed and the statements made within, is for informational and advertising purposes only and should not be construed as investment-advice, and does not constitute an offer to sell any securities, nor is it to be construed as a solicitation to purchase any securities in any state or other jurisdiction where the offer or sale is not permitted. The information to prepare this report is believed to be from reliable sources, but no representation is made as to the accuracy or completeness of such information. Investment in securities carries a high degree of risk and involves risks and uncertainties, which may result in investors losing all of their invested capital. Past performance does not guarantee future results. The information contained herein contains “forward-looking statements,” within the meaning of Section-27A of the Securities Act-of-1933 and Section 21E of the Securities Exchange Act-of-1934.
Forward-looking statements are based upon expectations, estimates and projections at the time the statements are made and involve risks and uncertainties that could cause actual events to differ materially from those anticipated. Forward-looking statements may be identified through the use of words such as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should, or might occur. Any statements that express or involve predictions, expectations, beliefs, plans, projections, objectives, goals or future events or performance may be forward-looking statements. Factors that could cause actual results to differ materially include but are not limited to adverse economic conditions, intense competition, lack of meaningful research results, inadequate capital, termination of contracts or agreements, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other key personnel, and other risks detailed in the reports filed with the Securities and Exchange Commission by the companies who are mentioned in this periodical. Readers should consult with their own professional investment, tax and portfolio advisors before making any investment decision and should independently verify all information herein.
More complete information about any of the companies mentioned in this periodical is available from the website of the Securities and Exchange Commission, at sec.gov, and copies of their filings may be read without charge and copies obtained at prescribed rates from the public reference facilities of the Commission, at 450 Fifth Street, NW, Washington, DC 20549.
Buying and Selling of Shares OTCtipReporter.com intends to sell its shares. OTCtipReporter.com may sell its shares for less than target prices given in opinions.
OTCtipReporter.com affiliates, officers, directors and employees may have also bought or may buy the shares discussed in this report and may profit in the event those shares rise in value.
OTCtipReporter.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. There are risks involved Always remember that OTCtipReporter.com are not analysts and investing in securities such as the ones listed within are for high risk tolerant individuals only and not the general public. Whether you are an experienced investor or not you should always consult with a broker before purchasing or selling any securities viewed on OTCtipReporter.com. If at any time you wish to be removed from our list simply
Related posts:
- Put SPEX On You RADAR Immediately!
- Member Alert week of 1/18/11
- Tuesday Alert week of 1/18/11
- Lebed.biz Alert – Extremely Important Update